3 Excellent Dividend Stocks to Buy on the Dip

The article is constructive on AbbVie, Walmart, and Becton, Dickinson as long-term dividend names, highlighting 50+ consecutive years of payout increases for all three. AbbVie’s Skyrizi/Rinvoq growth, Walmart’s e-commerce and digital advertising momentum, and Becton, Dickinson’s recurring consumables base and GLP-1 exposure are presented as key supports. The piece is primarily opinion-driven stock-picking commentary rather than fresh company-specific news, so near-term market impact should be limited.

Analysis

The shared setup here is not “high yield” but defensive compounding with optionality. In a slowing-growth / sticky-inflation tape, firms with pricing power and recurring consumables can quietly outperform because they defend margins while the market overweights cyclical earnings pressure; that favors WMT and BDX more than ABBV in the next 3-6 months. The second-order effect is that capital-return franchises often become bond proxies when real rates stabilize, so these names can re-rate even without major fundamental acceleration.

The market is likely underappreciating the asymmetry in the non-core businesses: WMT’s retail media and e-commerce mix can expand gross profit per visit, while BDX’s consumables base creates operating leverage once the lower-growth segment is removed from the mix. For ABBV, the key is not the current pipeline headline but whether management can bridge the post-patent period with enough cadence of label expansions and life-cycle management to keep revenue growth in the mid-single digits; if that cadence slips, the stock becomes a yield vehicle rather than a total-return compounder. In other words, the fundamental risk is less a binary “pipeline works/doesn’t work” outcome and more a timing gap between patent erosion and new product monetization.

The consensus appears to be over-discounting near-term softness at WMT and BDX while still treating ABBV as the cleanest dividend story. I think that framing is incomplete: WMT has the clearest secular reinvestment runway, BDX has the most re-rating potential if consumables growth inflects, and ABBV carries the highest headline quality but also the most path-dependence. The key catalyst window is 1-2 earnings cycles; if guidance stabilizes, these names can work as low-volatility longs even if the broader market de-risks.

Key Decisions for Investors

• Go long WMT vs. XRT on a 3-6 month horizon; the thesis is that scale and ad/e-commerce mix protect margins better than general retail, with a 2:1 upside/downside profile if consumer spending weakens further.
• Add BDX on weakness over the next 1-2 quarters; treat it as a staged entry because the refocused portfolio can drive multiple expansion if management shows even modest organic growth acceleration, creating 15-20% upside versus low-teens drawdown risk.
• Hold ABBV only as a cash-flow anchor, not an aggressive momentum long; pair it against a basket of higher-beta healthcare names if you want to isolate yield while reducing patent-transition risk.
• Use covered calls on ABBV and BDX into earnings to monetize implied volatility; these are more likely to grind than gap, and call overwrites can add 2-4% annualized carry with limited opportunity cost.
• If entering fresh capital, favor WMT > BDX > ABBV for the next 6 months; the ordering reflects better visibility on multiple expansion and lower dependence on product-cycle execution.